Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B-Right AI Platform through GE HealthCare’s Voluson Solution Store, bringing advanced AI support directly into routine prenatal care.

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI-Lung. The company had previously announced MDR certification in November of 2025.

The RevealDX technology characterizes nodules by producing a Malignancy Similarity Index (mSI), a score that helps radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on over 1,500 patients from a variety of cohorts. 

Feb. 4, 2026 — A new review published in the American Journal of Roentgenology (AJR) finds that advances in CT technology over the past 25 years have enabled routine radiation dose reductions by a factor of 2 to 10, while preserving diagnostic performance when applied appropriately.

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) together are calling for greater awareness of what today’s radiotherapy offers to patients and the global health care system: a cornerstone of modern, multidisciplinary cancer care, grounded in precision, personalization and continuous innovation.

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's recently-released National Cancer Plan for England. 

The Plan reflects priorities long highlighted by the RCR, the body representing senior doctors responsible for cancer diagnosis and treatment, to:  

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM LesionID Pro,1 an innovative solution from its MIM software portfolio that transforms whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies into a significantly simplified process.

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients.

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now